Urological Department, The Affiliated Hospital and Clinical Medical College of Chengdu University, Chengdu, Sichuan, China.
Urological Department, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Urol J. 2021 Apr 11;18(3):247-251. doi: 10.22037/uj.v18i.4831.
To explore the efficacy of 5-ARIs in PCA (Prostate Cancer).
Searching through the major medical databases such as PubMed, Science Citation Index, EMBASE, Medline, Web of Science, Cochrane Library for all published studies in English until 2018. The following search terms were used: "Finasteride", "dutasteride", "5α reductase inhibitors", "5-ARIs", "prostate cancer", "prostate neoplasm" and the additional related studies were manually searched. Newcastle-Ottawa Scale (NOS) assessed the qualities of studies, and the outcome measures were observed by RR or OR with 95% CIs.
We included 9 eligible studies for analyses from 2011 to 2017. We found that 5-ARIs group may have fewer progression (OR = 0.48 95%CI: 0.37-0.61 P < 0.00001, I2=4% p = 0.39) and lower pathological progression (OR = 0.46; 95%CI: 0.29-0.73; p = 0.001, I2=0% p = 0.45), compared with control groups. However, the OS did not show significant difference between two groups (OR=1.10; 95%CI:0.90-1.35; P = 0.35, I2 = 93% P < .00001 ).
The use of 5-ARIs could prevent progression in PCA patients both clinical and pathological.
探讨 5-ARIs 在 PCA（前列腺癌）中的疗效。
通过检索 PubMed、科学引文索引、EMBASE、Medline、Web of Science、Cochrane 图书馆等主要医学数据库，检索截至 2018 年发表的所有英文研究。使用的搜索词包括：“非那雄胺”、“度他雄胺”、“5α 还原酶抑制剂”、“5-ARIs”、“前列腺癌”、“前列腺肿瘤”，并手动检索了其他相关研究。采用纽卡斯尔-渥太华量表（NOS）评估研究质量，观察指标为 RR 或 OR 及其 95%CI。
我们纳入了 2011 年至 2017 年的 9 项符合条件的研究进行分析。我们发现，5-ARIs 组进展（OR=0.48，95%CI：0.37-0.61，P<0.00001，I2=4%，p=0.39）和病理进展（OR=0.46；95%CI：0.29-0.73；p=0.001，I2=0%，p=0.45）的可能性较小。然而，两组的 OS 没有显著差异（OR=1.10；95%CI：0.90-1.35；P=0.35，I2=93%，P<0.00001）。
5-ARIs 的使用可以预防 PCA 患者的临床和病理进展。
